(Business Wire) Aimmune Therapeutics Inc. (NASDAQ:AIMT) announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,499,999 shares of common stock. Aimmune’s common stock began trading on The NASDAQ Global Select Market on August 6, 2015, under the symbol AIMT.
BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as joint book-running managers for the offering.
Aimmune Equity Analysis
Aimmune Therapeutics Inc. (NASDAQ:AIMT) opened trading today as $25.52 and is trading in the range of 22.19-26.67 today. Aimmune’s current market cap stands at $1.04 billion.
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. Its characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults that has completed a Phase II study. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.